Project Grant R43DK126521
Award Date 3/1/21
Completion Date 2/28/23
Dollars Obligated $784K
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Louisville, CO 80027, USA
Similar Awards
- This $335,410 federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) supports the development of a needle-free microneedle array patch (MAP) for delivering a GLP-1 receptor agonist to treat type 2 diabetes. The grant recipient, Vaxess Technologies, Inc., is a biotechnology company specializing in innovative MAP technologies for drug and vaccine...
- This Project Grant award, valued at $275,275 and provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports the development of a miniaturized and flexible continuous glucose monitoring (CGM) platform called "GlucoSoft" by Integrated Medical Sensors Inc., a minority-owned small disadvantaged business. The goal is to create a scalable, user-friendly, and...
- This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $284,999 to Integrated Medical Sensors Inc. to develop and validate efficient algorithms for real-time glucose monitoring on a multi-sensor integrated platform. The goal is to create a scalable, user-friendly, and affordable continuous glucose monitoring (CGM) system to improve...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $719,250 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Biotherapeutics, Inc., a clinical-stage biotech company in Virginia. The grant supports the development of novel, oral therapeutic candidates for the treatment of pre-diabetes and type 2 diabetes (T2D). The specific aims are to: 1) Evaluate the therapeutic efficacy of the lead drug candidate...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded a $613,744 Project Grant to Geminii Inc. to develop a "sleep to treat" technology that uses electromagnetic fields to reprogram metabolism and improve insulin sensitivity for the treatment of type 2 diabetes. The award, with an ultimate completion date of April 30, 2026, aims to demonstrate the feasibility of...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $745,249 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to the University of Notre Dame DU Lac. The project aims to develop a once-weekly and glucose-responsive insulin formulation. The research focuses on chemically modifying insulin with a novel glucose binder and a dendrimer carrier to create a subcutaneous nanocomplex insulin depot that can...
- The National Science Foundation (NSF) Division of Chemical, Bioengineering, Environmental, and Transport Systems awarded a $450,000 Project Grant to the Texas A&M Engineering Experiment Station (Tees) to develop an injectable, grain-of-rice size glucose biosensor for continuous blood sugar monitoring. The key products or services to be provided under this 3-year grant include: Developing an injectable glucose biosensor comprised of a self-cleaning membrane and a near-infrared fluorescence...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $284,517 Project Grant (CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research) to Electronic Biosciences, Inc. to develop a point-of-care diagnostic assay for detecting autoantibodies associated with type 1 diabetes (T1D). This project aims to leverage nanopore technology to create a rapid, cost-effective test for screening populations, especially children, for T1D biomarkers that appear...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $306,500 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Qrono, Inc., a for-profit medical research and development company. The grant funding supports the development of QR402, a first-in-class, oral nanomedicine that uses an AMPK pathway agonist to target intestinal dendritic cells and restore immunological tolerance as a preventative therapy for type 1 diabetes. The goal is to...
- This federal Project Grant award of $152,379.00, provided by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), aims to develop an AI-based framework that can identify digital biomarkers of glycemic control and patient-reported outcomes for personalized diabetes management. The goal is to leverage physiological signals, glucose management data, and...